Evidence map›Paper›PMID 41627045›Full record

ArticleJournal of medicinal chemistry2026

Discovery of a Neuroprotective Diosgenin Derivative as a Novel Antidepressant Candidate Targeting LPS-TLR4 Signaling.

Younghun Yoo, Soo Yeon Baek, Hyelim Lee, Jeehee Lee, Hyowon Lee, Haeun Lee, Hyeonji Ma, Yujin Kim, Hoon-Seong Choi, Jeong Tae Lee and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Younghun YooMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Soo Yeon BaekMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Hyelim LeeMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Jeehee LeeMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Hyowon LeeCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Haeun LeeMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.ORCID 0009-0005-8385-8006
Hyeonji MaMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Yujin KimMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Hoon-Seong ChoiResearch Animal Resources Center, Research Resources Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Jeong Tae LeeDepartment of Chemistry and Institute of Applied Chemistry, Hallym University, Chuncheon 24252, Republic of Korea.
Jae Yeol LeeResearch Institute for Basic Sciences and Department of Chemistry, College of Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.ORCID 0000-0001-6622-6692
Min-Ho NamDivision of Bio-Medical Science and Technology, KIST School, University of Science and Technology, Seoul 02792, Republic of Korea.ORCID 0000-0002-6191-1268
Sanghee LeeMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.ORCID 0000-0002-7765-5916
Byungsun JeonMedicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.ORCID 0000-0003-4189-6774

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression is a widespread and increasing mental disorder, yet current antidepressants, including tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), often cause notable side effects and limited efficacy. Hence, safer therapeutic options are needed. Diosgenin, a phytosteroid sapogenin from the Dioscoreaceae plants, has demonstrated therapeutic potential for neurological disorders but is hindered by unclear target mechanism, poor solubility, and limited bioavailability. Here, we synthesized diosgenin derivatives and evaluated their biological activities. Among them, compound

Indexed as

Antidepressive AgentsDiosgeninLipopolysaccharidesNeuroprotective AgentsSignal TransductionToll-Like Receptor 4AnimalsDepressionDrug DiscoveryHumansMaleMiceMolecular Docking SimulationNitric OxideStructure-Activity RelationshipAntidepressive AgentsDiosgeninLipopolysaccharidesNeuroprotective AgentsNitric OxideToll-Like Receptor 4

Identifiers

PMID41627045
PMCPMC12910651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.